Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4126
Century Therapeutics
IPSC
$364M
| $41.2K | ﹤0.01% |
16,148
-315
| -2% | -$996 |
|
4127
Monte Rosa Therapeutics
GLUE
$1.4B
| $41.2K | ﹤0.01% |
11,009
-10,739
| -49% | -$54.8K |
|
4128
First Northwest Bancorp
FNWB
$109M
| $41.2K | ﹤0.01% |
4,247
| – | – |
|
|
GPGI
4129
GPGI Inc
GPGI
$3.83B
| $41.1K | ﹤0.01% |
7,282
-6,818
| -48% | -$37.7K |
|
4130
ASP Isotopes
ASPI
$504M
| $41.1K | ﹤0.01% |
+13,433
| New | +$51.8K |
|
4131
Assembly Biosciences
ASMB
$498M
| $41.1K | ﹤0.01% |
2,994
| – | – |
|
|
AFMD
4132
DELISTED
Affimed
AFMD
| $41K | ﹤0.01% |
7,516
| – | – |
|
4133
Nerdy
NRDY
$106M
| $40.3K | ﹤0.01% |
24,152
-21,439
| -47% | -$47.1K |
|
4134
Pioneer Bancorp
PBFS
$432M
| $40K | ﹤0.01% |
3,991
-4,110
| -51% | -$39.1K |
|
4135
Similarweb
SMWB
$628M
| $39.8K | ﹤0.01% |
5,121
-4,669
| -48% | -$36.4K |
|
4136
State Street SPDR Bloomberg Emerging Markets Local Bond ETF
EBND
$2.26B
| $39.8K | ﹤0.01% |
2,000
| – | – |
|
4137
1stdibs.com
DIBS
$149M
| $39.7K | ﹤0.01% |
+8,841
| New | +$48.3K |
|
4138
Porch Group
PRCH
$1.64B
| $39.5K | ﹤0.01% |
26,171
+24,807
| +1,819% | +$69.1K |
|
4139
Geospace Technologies
GEOS
$94.6M
| $39.5K | ﹤0.01% |
4,395
-10,069
| -70% | -$113K |
|
4140
Offerpad Solutions
OPAD
$18.3M
| $39.4K | ﹤0.01% |
892
+236
| +36% | +$14.7K |
|
|
RGLS
4141
DELISTED
Regulus Therapeutics
RGLS
| $39.1K | ﹤0.01% |
+21,928
| New | +$50.9K |
|
4142
Ubiquiti
UI
$33.7B
| $39K | ﹤0.01% |
268
-36,249
| -99% | -$4.65M |
|
4143
XBiotech
XBIT
$68M
| $39K | ﹤0.01% |
+7,582
| New | +$58.5K |
|
4144
Priority Technology Holdings
PRTH
$535M
| $38.7K | ﹤0.01% |
7,323
-5,976
| -45% | -$22.6K |
|
4145
Hyperfine
HYPR
$92.9M
| $38.3K | ﹤0.01% |
45,000
| – | – |
|
4146
Lifecore Biomedical
LFCR
$166M
| $38.2K | ﹤0.01% |
+7,455
| New | +$44.1K |
|
4147
Sanara MedTech
SMTI
$311M
| $38.2K | ﹤0.01% |
1,355
-1,344
| -50% | -$42.2K |
|
4148
Aemetis
AMTX
$106M
| $38.2K | ﹤0.01% |
12,680
-29,414
| -70% | -$112K |
|
|
VISL
4149
DELISTED
Vislink Technologies, Inc. Common Stock
VISL
| $38.1K | ﹤0.01% |
8,750
| – | – |
|
4150
Veru
VERU
$36M
| $38K | ﹤0.01% |
+4,516
| New | +$52.2K |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.